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Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory
multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone.
Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 and
January 2016 were screened. The patients were followed until March 2016 after CFZ treatment.
Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. The median age was 62 (47–76) years. The median
number of prior treatment lines was 3 (2–7). The median number of administered cycles of treatment for CFZ was 4 (1–10). The median
overall response rate was 26.3%. The most common hematological adverse events were anemia and thrombocytopenia (38%). The most
common nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient died
because of pneumonia during the treatment period. The median duration of response rate and time to next therapy were 8 (7–9) and 3
(2–16) months, respectively. The median overall survival was 8 (0.5–33) months.
Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreated
R/R-MM patients.
Key words: Multiple myeloma, carfilzomib, proteasome inhibitors, novel therapies

1. Introduction
Multiple myeloma (MM) is characterized by the
neoplastic proliferation of plasma cells and accounts for
approximately 10% of hematologic malignancies (1,2). In
newly diagnosed cases of MM, initial treatment depends
on whether the patient is a candidate for autologous stem
cell transplant (ASCT) with high-dose melphalan. Younger
(<65 years) and fit patients are potential candidates for
ASCT with high-dose melphalan. Before the ASCT, VAD
(vincristine, doxorubicin, dexamethasone), bortezomibbased, or thalidomide-based regimens are being used
as induction therapy (3). Melphalan, bortezomib, or
immunomodulatory (thalidomide, lenalidomide)-based
regimens are preferred for initial treatment in elderly (>65
years) and unfit patients who are ineligible for ASCT (4).
MM, which has a high response rate to first-line
treatments and long durations of remission, has a high risk
of relapse, and relapsed/refractory MM (RR-MM) is more
resistant than de novo disease to known therapeutic agents.
* Correspondence: drayseorucuysal@gmail.com
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Remissions are shorter and the possibility of toxicity is
higher with recurrent disease (5). In recent years, the use
of thalidomide and lenalidomide, immunomodulatory
drugs (IMiDs), and bortezomib, a proteasome inhibitor,
increased the success of survey and remission durations
in RR-MM. However, patients with RR-MM may develop
resistance and succumb to the disease. Patients who are
resistant to both lenalidomide and bortezomib have a poor
prognosis and are accepted as cases of double-refractory
MM (6,7). The median progression-free survival and
overall survival (OS) are respectively 5 and 9 months in
patients with double-refractory MM (8).
Carfilzomib (CFZ) is a new promising agent for doublerefractory MM. CFZ is a second-generation proteasome
inhibitor with significant activity among RR-MM patients.
In this study, we evaluated the efficacy and toxicity of CFZ
in our patients who received bortezomib and lenalidomide
prior to our study and who developed RR-MM.
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2. Materials and methods
2.1. Patients
In this study, 21 RR-MM patients treated with CFZ plus
dexamethasone between October 2013 and January 2016
in the Hematology Department of Ege University were
retrospectively screened. The patients were followed
until March 2016. During the aforementioned period,
carfilzomib was not available in our country, so we
used the drug with special permission from our health
authority for patients who were resistant to bortezomib
and lenalidomide.
Patients had received at least 2 lines of prior regimens for
relapsed/refractory disease according to the International
Myeloma Working Group (IMWG), including bortezomib,
thalidomide or lenalidomide, an alkylating agent, or an
anthracycline alone or in combination. The International
Scoring System (ISS) was used for prognostic evaluation at
the beginning of treatment (9).
Side effects (hematological or nonhematological) and
treatment dose of carfilzomib, duration of treatment,
response assessments, response rates, and survival status
of patients were evaluated. Overall response rate (ORR; the
proportion of patients with stringent complete response
[sCR], complete response [CR], very good partial response
[VGPR], and partial response [PR]) was assessed according
to the IMWG Uniform Response Criteria (10). Adverse
events were assessed at each visit and graded according to
National Cancer Institute Common Terminology Criteria
(NCI-CTC) for Adverse Events (Version 4.0) (11).
2.2. Treatment
Carfilzomib was given by intravenous infusion over 2–10
min on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle;
the daily dose for cycle 1 was 20 mg/m2 and the dose was
increased to 27 mg/m2 per day in cycle 2 and subsequent
cycles. Doses were modified at the treating physician’s
discretion. All patients received dexamethasone at 20–40
mg/week. Intravenous and oral hydration was given prior
to CFZ.
2.3. Statistical analysis
Patient characteristics were summarized using descriptive
statistics such as median, minimum and maximum were
used for qualitative data, and a number with percentage
was used for categorical data. OS was determined by
Kaplan–Meier analysis. OS was defined as the beginning
of CFZ treatment to death from any cause or last contact.
Time to next therapy (TtNT) was defined as the time from
the first dose of CFZ to the beginning of the next therapy.
The duration of response (DOR) was calculated from the
time of first recorded achievement of a particular response
level, i.e. PR, VGPR, CR, or sCR, and includes only patients
responding to the progression of disease or death without
disease progression.

3. Results
3.1. Patients and disease characteristics
In this study, 21 RR-MM patients treated with CFZ were
evaluated; 10 (47.6%) of them female and 11 (52.4%)
of them male. The median age at CFZ initiation was 62
(range: 47–76) years. The median time from diagnosis
of MM to the beginning of CFZ was 45 (range: 20–137)
months. Before CFZ initiation, all patients were assessed
as having relapsed/refractory disease. Patients and disease
characteristics are given in Table 1.
3.2. Treatment characteristics
Patients had received a median of 3 lines of therapy prior to
CFZ (range: 2–7). CFZ was given as 3rd line therapy for 9
patients, 4th line therapy for 6 patients, 5th line therapy for
5 patients, and 8th line therapy for 1 patient. Refractoriness
to bortezomib and IMiDs prior to CFZ treatment was seen
in 42.8% and 61.9% of patients, respectively. Thirteen
patients (61.9%) were refractory in their last treatments.
Table 1. Patients and treatment characteristics at the beginning
of CFZ.
Patients

N: 21 (%)

Male

10 (47.6)

Female

11 (52.4)

Age (median)

62 (range: 47–76)

ECOG
0–2

15 (71.4)

3–4

6 (28.6)

ISS
II

6 (28.6)

III

15 (71.4)

M protein
IgG

11 (52.3)

IgA

6 (28.6)

Light chain

4 (19.1)

Light chain
Kappa

15 (71.4)

Lambda

6 (28.6)

Extramedullary plasmacytoma (%)

4.7

Prior lines of therapy (median)

3 (2–7)

Bortezomib resistance (%)

42.8

IMiD resistance (%)

61.9
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The median time from last treatment to CFZ initiation was
2 months (range: 0.5–21). The median time from diagnosis
to CFZ initiation was 45 months (range: 20–137). The
most common last therapy before CFZ was lenalidomidebased treatment (61.9%). Fourteen patients (66.6%) had
prior ASCT.
3.3. Treatment characteristics with carfilzomib
The median number of administered cycles of treatment
for CFZ was 4 (range: 1–10). The majority of patients
(90.5%) received CFZ according to the 20/27 mg/m2 dose
schedule. Two patients (9.5%) received CFZ at a maximal
dose as 56 mg/m2. All patients received CFZ therapy as a
combination with dexamethasone.
Two patients died before response assessment, and
therefore they were not included in the response analysis.
The ORR was 26.3%, with 5 patients with PR in this study.
Eight (42.1%) patients had disease progression and 6
(31.6%) patients had SD. Their treatment regimens were
changed. The median DOR was 8 (range: 7–9) months.
The median TtNT and OS were 3 (range: 2–16) and 8
(range: 1–33) months, respectively.
3.4. Adverse events
During the treatment, no infusion-related side effects were
observed in any patients. The most common hematological
adverse events were thrombocytopenia and anemia (38%).
The most common nonhematological adverse event
was fatigue (71.4%). At baseline, 40% of patients had
neuropathy. Two patients (9.5%) experienced new-onset
neuropathy but no patients had worsening neuropathy.
CFZ-related adverse events are illustrated in Table 2.

Table 2. Treatment-related adverse events.
All grades (%)

Grade ≥3 (%)

Thrombocytopenia

8 (38)

3 (14.2)

Neutropenia

6 (28.5)

4 (19)

Anemia

8 (38)

3 (14.2)

Fatigue

15 (71.4)

6 (28.5)

Nausea

14 (66.7)

4 (19)

Dyspnea

3 (14.2)

1 (4.8)

Pneumonia

2 (9.5)

1 (4.8)

Peripheral neuropathy

2 (9.5)

0

Acute renal failure

1 (4.8)

0

Cerebrovascular event

1 (4.8)

1 (4.8)

Hematological

Nonhematological
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Seven patients died at the end of the study. One patient
died because of cerebrovascular event and 1 patient died
because of pneumonia during the treatment period. The
treatment-related mortality rate was 9.5%. Five patients
died because of disease progression after the CFZ
treatment was changed.
4. Discussion
Carfilzomib is an irreversible second-generation
proteasome inhibitor and received fast approval from the
US FDA for RR-MM patients in July 2012. Robust and
durable efficacy and acceptable safety and high tolerability
profile were proven in patients with clinical trials (12). In
this study, we evaluated the efficacy and safety of CFZ plus
dexamethasone treatment in heavily pretreated patients
who had received prior bortezomib, immunomodulatory
agents like thalidomide or lenalidomide, and alkylating
agents.
In our group, the ORR was 26.3% and the best
response was PR. The median DOR was 8 months. The
median number of prior treatment lines was 3 and 13
patients (61.9%) were refractory in their last treatments.
Refractoriness to bortezomib and IMiDs prior to CFZ
treatment was seen in 42.8% and 61.9% of patients,
respectively. Fourteen patients (66.6%) had prior ASCT.
The median OS was 8 months. In the pivotal study, PX171-003A1, 266 patients with RR-MM who had received
at least 2 prior treatment regimens were treated with
single-agent CFZ. The median number of prior therapies
was 5, 74% of patients had been treated with autologous
transplantation, and the majority of patients (95%) were
judged refractory to their most recent therapy. The ORR
was 23.7% with a median DOR of 7.8 months. The median
OS rate was 15.6 months (12). In another phase 2 singleagent CFZ study, the best ORR was 17.1% and the median
DOR and OS were >10.6 and 29.9 months, respectively.
The median number of prior therapies was 3 and 80% of
patients had been treated with autologous transplantation
(13). In the randomized phase 3 study of CFZ (FOCUS),
the median OS was 10.2 vs. 10.0 months with carfilzomib
vs. low-dose corticosteroids. There was no significant
improvement between groups. The median ORR was 19.1%
in the CFZ group and 11.4% with low-dose corticosteroids
(14). Although the number of patients was limited, our
results were compatible with literature.
In our group, the most common hematological
adverse events were thrombocytopenia (38%), anemia
(38%), and neutropenia (28.5%). The most common
nonhematological adverse events were fatigue (71.4%),
nausea (66.7%), and dyspnea (28.5%). Adverse events
were manageable. In the literature, hematological adverse
events are the prominent toxicity of CFZ treatment. The
most common hematological adverse events were found
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to be thrombocytopenia (28.3%–39%), anemia (26.8%–
56%), and neutropenia (15%–25.7%). The most common
nonhematological adverse events were fatigue (49%–
62.9%, 77.8%), nausea (20%–60%), and dyspnea (34%–
37.1%) (12–15). All these side effects were temporary and
easy to manage, but bleeding due to thrombocytopenia
or neutropenic fever may cause severe clinical conditions
(16). Our findings are compatible with the literature. In a
study from Israel, both hematological (76.3% for anemia,
75.6% for thrombocytopenia) and nonhematological
(77.8% for fatigue) adverse events were reported to be
higher than in previous studies. It was reported that the
higher number of adverse events were associated with
the combination of drugs (17). The treatment-related

mortality rate was 9.5% in our group. This mortality rate
was higher than those seen in the literature (4.1%–5.2%)
(12,17). It should be kept in mind that our study group had
a small number of patients and the cerebrovascular event
that was one of the causes of death was only suspiciously
related to carfilzomib.
Our study had some limitations. First, it was a
retrospective study with a potential bias concerning
patients and methods. Second, the number of patients was
limited since it was a single-institution experience.
Despite the small number of patients, our results
suggest that carfilzomib provides acceptable responses in
heavily pretreated RR-MM patients. Carfilzomib seems to
be tolerable and the side effects were manageable.
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